Alumis Inc. (ALMS) fundamentals score
Alumis is a clinical stage biopharmaceutical company with an initial focus on developing its two Tyrosine Kinase 2 (“TYK2”) inhibitors: envudeucitinib (“envu”), formerly known as ESK-001, a second-generation inhibitor that it is developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (“CNS”) penetrant allosteric TYK2 inhibitor.
Pharmaceutical Preparations · Healthcare · Listed on NASDAQ
Overall: 2.9 out of 10, Unhealthy fundamentals
- Growth: 1.5/10
- Profitability: 1.0/10
- Financial health: 6.0/10
- Earnings quality: 5.5/10
- Valuation: 1.5/10
Scores are calculated from Alumis Inc.’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10